Daiichi Sankyo joins Milner Therapeutics Consortium

We are delighted to announce that Daiichi Sankyo has joined the Milner Therapeutics Consortium as our tenth pharma partner. The Milner team works closely with this unique grouping of pharma companies to advance research towards new therapeutics across multiple disease areas, catalysing pre-clinical research collaborations with academics across Cambridge and providing early sight of start-ups. The Consortium has recently been renewed until 2029, providing exciting opportunities for new partnerships around priority industry challenges.

This collaboration is a key step for the external reach of Daiichi Sankyo in the UK, working through its Daiichi Sankyo Research Institute in Munich. Through the Milner Consortium, Daiichi Sankyo will be able to establish research collaborations of mutual benefit with academics across Cambridge. The company has a key focus on developing novel medicines in oncology, as well as other research areas centred around cardiovascular diseases and immune disorders, and these will be priorities for engagement here in Cambridge.

How to work with us:

If you are a pharma company who is interested in the Consortium model or an academic with a potential pre-clinical collaborative project that would benefit from industry expertise and know-how, please contact us at any time for a meeting.

Read the full news piece on the Milner website.